Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  CANADIAN NATIONAL STOCK EXCHANGE  >  Cresco Labs Inc.    CL   CA22587M1068

CRESCO LABS INC.

(CL)
  Report
Delayed Quote. Delayed CANADIAN NATIONAL STOCK EXCHANGE - 10/23 03:59:58 pm
9.89 CAD   +0.10%
10/18CRESCO LABS : CEO talks legal marijuana industry challenges
AQ
10/18CRESCO LABS : CEO talks legal marijuana industry challenges
AQ
10/15Cannabis companies, betting on a Biden win, ready IPOs
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cresco Labs : CEO talks legal marijuana industry challenges

share with twitter share with LinkedIn share with facebook
10/18/2020 | 10:11am EDT

LOS ANGELES (AP) — Demand for marijuana products in U.S. states where they are legal in some form has been resilient this year, despite the pandemic.

In California and other states that account for most of the retail sales of marijuana for recreational use, sales are up 8.5% from a year ago, according to data from industry tracker Headset.

Charlie Bachtell, CEO and co-founder of Chicago-based Cresco Labs, credits strong sales this year to growing marijuana demand and retailers having been deemed essential businesses during the pandemic.

Cresco Labs began growing and selling marijuana in Illinois in 2015, and as of this year has expanded to a total of nine states and Canada. Its sales more than tripled in the first half of this year to nearly $161 million. Its stock trades on the Canadian stock exchange and on over the counter markets in the U.S.

Only 11 states including Oregon and Colorado allow the retail sales of marijuana for recreational use, but advocates are pushing to expand access elsewhere. The pandemic has ravaged states’ finances, making legalizing marijuana -- and collecting high excise sales taxes -- more appealing to state governments. Six states will vote on marijuana-related ballot initiatives in next month's elections.

Bachtell recently spoke to The Associated Press about how Cresco has prospered during the pandemic and the challenges facing the U.S. cannabis industry. The interview has been edited for length and clarity.

Q: How have your sales fared during the pandemic and recession?

A: The easiest way for me to describe it is to compare second-quarter results to first-quarter results. We’re in nine markets across the country, nine different states, and we saw at least 30% sequential growth, quarter-over-quarter, in all of our nine states except for one, Massachusetts. And Massachusetts was one of the very limited states that did not deem the adult-use program essential.

Q: Would you say the pandemic's been a boon for legal marijuana, given so many people are sheltering in place and looking for ways to manage the stress of it all?

A: You can find the correlation there, for sure. They have more time on their hands, working from home, being at home, and finding something else to help them take their mind off the stress. All of the above are factors in what we saw with greater acceptance, a greater consumer base with greater spending, so far, during this era. We tend to be in the highly regulated newer markets -- Illinois, Pennsylvania, Ohio, New York -- but they’re seeing growth in well-established markets like Colorado, Washington, Oregon and California. To see growth in those markets is even more telling.

Q: What’s the biggest challenge facing the industry?

A: The main thing holding the industry back is access to capital that would allow the infrastructure to be built, that then creates the growth, the jobs, the revenue. The fundamental restraint that still hangs over this industry is it’s difficult to capitalize it, but once that hurdle is cleared, even if nothing else is done, you’ll see explosive growth.

Q: The SAFE Banking Act, which would free up banks to do business with licensed marijuana companies, has stalled in the GOP-controlled Senate. How confident are you this and other measures favored by the cannabis industry will become law in the near future?

A: The conversations are changing from ‘Why would we do this?’ to ‘Why wouldn’t we do this?’ Even at the federal level, as it relates to how banking occurs, you’ll find support for this on both sides of the aisle. And it’s less about ‘if’ and more about ‘how’ to do it. Cannabis, from my perspective, is in a very good position.

Copyright 2020 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News


share with twitter share with LinkedIn share with facebook
All news about CRESCO LABS INC.
10/18CRESCO LABS : CEO talks legal marijuana industry challenges
AQ
10/18CRESCO LABS : CEO talks legal marijuana industry challenges
AQ
10/15Cannabis companies, betting on a Biden win, ready IPOs
RE
10/14CRESCO LABS : Launches Remedi Cannabis Brand Into New York
BU
10/13CRESCO LABS : to Report Third Quarter 2020 Financial Results on November 18th, 2..
BU
10/07CRESCO LABS : Establishes Comprehensive Standards for Responsible Advertising & ..
BU
09/22CRESCO LABS : Announces Approval for Tenth Illinois Dispensary in Naperville
BU
09/17CRESCO LABS : Bolsters Leadership Team With Three Senior Promotions
BU
09/09CRESCO LABS : Launches Good News Cannabis Brand
BU
08/24CRESCO LABS : Announces Upcoming Conference Participation
BU
More news
Financials (USD)
Sales 2020 408 M - -
Net income 2020 -58,1 M - -
Net Debt 2020 142 M - -
P/E ratio 2020 -38,8x
Yield 2020 -
Capitalization 1 677 M 1 677 M -
EV / Sales 2020 4,46x
EV / Sales 2021 2,53x
Nbr of Employees 1 800
Free-Float 20,5%
Chart CRESCO LABS INC.
Duration : Period :
Cresco Labs Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CRESCO LABS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Average target price 12,38 CAD
Last Close Price 9,89 CAD
Spread / Highest target 46,7%
Spread / Average Target 25,1%
Spread / Lowest Target 6,17%
EPS Revisions
Managers
NameTitle
Charles Bachtell Chief Executive Officer & Director
Thomas Joseph Manning Executive Chairman
David Ellis Chief Operating Officer
Dennis M. Olis Chief Financial Officer
Mo Dastagir Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
CRESCO LABS INC.10.75%1 677
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999